Targeted markets NovaSterilis serves complex medical devices, drug delivery, tissue engineering, biotherapeutics/API, and additive manufacturing, indicating multiple high-value application areas for cross-sell or upsell of scCO2 sterilization and decellularization services to medical device manufacturers and biotech firms.

Safety leadership Position NovaSterilis as a safety-first partner with sterility assurance level 10-6 and proven performance in preserving material integrity at low temperatures, highlighting its fit for temperature-sensitive products and regulatory-compliant sterilization needs.

Global health impact With over 300,000 surgeries treated using their processes in eight years, emphasize reliability, scale readiness, and potential for long-term contracts with OEMs and contract manufacturers seeking proven sterilization throughput.

Growth signals Active participation in industry events such as the European Society for Biomaterials conference signals a willingness to engage with potential customers, partners, and thought leadership opportunities to accelerate deal flow.

Financial entry Small revenue base in the $1–10M range presents an opportunity for targeted, high-value engagements with mid-market medical device and biotech companies seeking scalable scCO2 sterilization and decellularization capabilities to differentiate their products.